Go Deep
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,093 | -4.8 | 3.77 | 0.04 | 86.50 |
| Oct 2026 | 20,052 | -4.8 | 3.81 | 0.04 | 87.11 |
| Oct 2026 | 19,726 | -5.2 | 4.11 | 0.04 | 94.04 |
| Oct 2026 | 19,780 | -5.1 | 4.06 | 0.04 | 92.66 |
| Oct 2026 | 19,894 | -5.0 | 3.96 | 0.04 | 90.34 |
| Oct 2026 | 19,805 | -5.1 | 4.04 | 0.04 | 92.22 |
| Oct 2026 | 19,899 | -5.0 | 3.95 | 0.04 | 89.99 |
| Oct 2026 | 19,750 | -5.2 | 4.09 | 0.04 | 92.97 |
Lineage Cell Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,069,000.0 | 1,725,000.0 | 6,608,000.0 | 3,681,000.0 |
| Net Profit | 1,482,000.0 | -4,812,000.0 | 851,000.0 | -29,781,000.0 |
| EPS | 0.0 | -0.0 | — | -0.1 |
Lineage Cell Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 14,556,000.0 | 9,499,000.0 | 8,945,000.0 | 14,703,000.0 | — |
| Net Profit | -63,533,000.0 | -18,609,000.0 | -21,486,000.0 | -26,273,000.0 | — |
| EPS | -0.3 | -0.1 | -0.1 | -0.1 | — |
Lineage Cell Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 112,584,000.0 | 113,218,000.0 | 101,019,000.0 | 123,664,000.0 | — |
| Total Liabilities | 69,238,000.0 | 36,206,000.0 | 38,996,000.0 | 51,728,000.0 | — |
| Total Equity | 44,549,000.0 | 78,381,000.0 | 63,419,000.0 | 73,339,000.0 | — |
Owes vs Owns
Lineage Cell Therapeutics, Inc. owed $0.44 for every $1 it owned in Jun 2026, up from $0.42 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.44× | 0.61× | 0.32× | 0.39× | 0.42× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Lineage Cell Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 49.5%Receivables 0.8%Fixed assets (tangible) 4.2%Intangible assets 37.6%Other assets 7.9%
How it's funded — Dec 2025
Short-term debt 0.8%Long-term debt 1.4%Payables 2.1%Other liabilities 57.3%Shareholders' equity 38.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 55.8 | 47.8 | 35.5 | 57.9 |
| Receivables | 0.9 | 0.6 | 0.7 | 0.3 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 4.7 | 4.4 | 4.8 | 5.7 |
| Intangible assets | 42.4 | 57.2 | 57.2 | 57.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 8.8 | 3.2 | 2.8 | 2.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.9 | 1.2 | 0.9 | 1.0 |
| Long-term debt | 1.6 | 1.4 | 2.1 | 2.9 |
| Payables | 2.3 | 1.2 | 2.0 | 2.4 |
| Other liabilities | 64.5 | 32.5 | 34.0 | 45.4 |
| Shareholders' equity | 43.3 | 77.0 | 62.0 | 71.9 |
| Net tangible assets | 2.2 | 21.2 | 6.2 | 16.0 |
Lineage Cell Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -18,919,000.0 | -23,092,000.0 | -28,566,000.0 | 1,059,000.0 | — |
| Investing Activities | -13,457,000.0 | -2,308,000.0 | 46,449,000.0 | -46,159,000.0 | — |
| Financing Activities | 26,950,000.0 | 35,857,000.0 | 6,423,000.0 | 1,632,000.0 | — |